Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-18T21:58:24.464Z Has data issue: false hasContentIssue false

Currents in Contemporary Ethics: State Run Newborn Screening in the Genomic Era, or How to Avoid Drowning When Drinking from a Fire Hose

Published online by Cambridge University Press:  01 January 2021

Extract

Parents, providers, policy makers, and the public need to talk about the implications of advances in genomic technologies for state run newborn metabolic screening programs. Technologies, such as highly multiplex testing and whole genome sequencing, are raising old issues with new urgency and are posing new challenges that threaten to overwhelm newborn screening programs.

Newborn screening programs in their current form were born in the late 1960s. Robert Guthrie developed a screening test for phenylketonuria (PKU) that could be performed on blood spots collected on filter cards that Guthrie also developed. States rapidly established newborn screening programs, which were almost always mandatory, in response to advocacy by geneticists and parents. Although the programs initially varied in form and experienced significant pushback from the medical community, by the early 1970s, all states had established programs with centralized laboratories, and the medical community had come on board.

Type
JLME Column
Copyright
Copyright © American Society of Law, Medicine and Ethics 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

For the history of newborn screening, see, e.g., Tarini, B. A., “The Current Revolution in Newborn Screening: New Technology, Old Controversies,” Archives of Pediatric and Adolescent Medicine 161, no. 8 (2007): 767772; Newborn Screening Task Force, “Serving the Family from Birth to the Medical Home: A Report from the Newborn Screening Task Force Convened in Washington DC, May 10–11, 1999,” Pediatrics 106, no. 2, Pt. 2 (2000): 383427; Clayton, E. W., “Screening and Treatment of Newborns,” Houston Law Review 29, no. 1 (1992): 85148.CrossRefGoogle Scholar
Guthrie, R., “The Introduction of Newborn Screening for Phenylketonuria: A Personal History,” European Journal of Pediatrics 155, Supp. 1 (1996): S4S5.CrossRefGoogle Scholar
Wilson, J. M.G. and Jungner, Gunnar, “Principles and Practice of Screening Fro Disease,” World Health Organization, available at <http://whqlibdoc.who.int/php/WHO_PHP_34.pdf> (last visited August 10, 2010).Google Scholar
See, e.g, Diaz-Barrios, V., “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies. New York's Experience,” Pediatrics 83, no. 5, Pt. 2 (1989): 872875; Garrick, M. D., “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: Alternative Methods for Screening,” Pediatrics 83, no. 5, Pt. 2 (1989): 855857; Grover, R, “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: Newborn Screening in New York City,” Pediatrics 83, no. 5, Pt. 2 (1989): 819822; Harris, M. S. and Eckman, J. R., “Georgia's Experience with Newborn Screening: 1981 to 1985,” Pediatrics 83, no. 5, Pt. 2 (1989): 858860; Henry, D. D., “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: Parental Perspective,” Pediatrics 83, no. 5, Pt. 2 (1989): 910; Hernandez, S., “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: Social Work Perspective,” Pediatrics 83, no. 5, Pt. 2 (1989): 903905; Hurst, D., “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: Northern California's Experience,” Pediatrics 83, no. 5, Pt. 2 (1989): 868871; Kinney, T. R., Sawtschenko, M., Whorton, M., Shearin, J., Stine, C., Hofman, L., Safko, R., Vitaglione, T., and Kaufman, R. E., “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies. Techniques’ Comparison and Report of the North Carolina Experience,” Pediatrics 83, no. 5, Pt. 2 (1989): 843848; Mack, A. K., “Florida's Experience with Newborn Screening,” Pediatrics 83, no. 5, Pt. 2 (1989): 861863; Scott, R. B., “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: Survey of Comprehensive Centers for Sickle Cell Disease,” Pediatrics 83, no. 5, Pt. 2 (1989): 908909; Therrell, B. L. Jr., Simmank, J. L., and Wilborn, M., “Experiences with Sickle Hemoglobin Testing in the Texas Newborn Screening Program,” Pediatrics 83, no. 5, Pt. 2 (1989): 864867; Whitten, C. F., “Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: Perspective from the National Association for Sickle Cell Disease,” Pediatrics 83, no. 5, Pt. 2 (1989): 906907.Google Scholar
Parsons, E. P., Clarke, A. J., and Bradley, D. M., “Implications of Carrier Identification in Newborn Screening for Cystic Fibrosis,” Archives of Diseases of Child. Fetal Neonatal Education 88, no. 6 (2003): F467F471.CrossRefGoogle Scholar
See, e.g., UK Newborn Screening Programme Centre, “UK Newborn Screening Programme Centre,” available at <http://newbornbloodspot.screening.nhs.uk/> (screen for total of five disorders) (last visited August 10, 2010); Bodamer, O., Hoffmann, G., and Lindner, M., “Expanded Newborn Screening in Europe 2007,” Journal, of Inherited Metabolic Disease 30, no. 4 (2007): 439444 (range from 2–20 in 7 countries).CrossRefGoogle Scholar
Atkinson, K., Zuckerman, B., Sharfstein, J. M., Levin, D., Blatt, R. J., and Koh, H. K., “A Public Health Response to Emerging Technology: Expansion of the Massachusetts Newborn Screening Program,” Public Health Reports 116, no. 2 (2001): 122131.Google Scholar
National Newborn Screening and Genetics Resource Center, “Genetic and Newborn Screening Resource Center of the United States,” available at <http://genes-r-us.uthscsa.edu/> (last visited August 10, 2010).+(last+visited+August+10,+2010).>Google Scholar
Moyer, V. A., Calonge, N., Teutsch, S. M., and Botkin, J. R., “Expanding Newborn Screening: Process, Policy, and Priorities,” Hastings Cent Rep 38, no. 3 (2008): 3239.CrossRefGoogle Scholar
American College of Medical Genetics, “Newborn Screening: Toward a Uniform Screening Panel and System: Report for Public Comment,” available at <http://www.mchb.hrsa.gov/screening/> (last visited August 10, 2010).+(last+visited+August+10,+2010).>Google Scholar
Botkin, J. R., Clayton, E. W., Fost, N. C., Burke, W., Murray, T. H., Baily, M. A., Wilfond, B., Berg, A., and Ross, L. F., “Newborn Screening Technology: Proceed with Caution,” Pediatrics 117, no. 5 (2006): 17931799.CrossRefGoogle Scholar
See, e.g., Save Babies Through Screening Foundation, Inc. “Newborn Screening Saves Babies One Foot at a Time,” available at <http://www.savebabies.org/> (last visited August 10, 2010).+(last+visited+August+10,+2010).>Google Scholar
Clayton, E. W., “Lessons to Be Learned From the Move toward Expanded Newborn Screening,” in Baily, M. A. and Murray, T. H., eds., Ethics and Newborn Genetic Screening: New Technologies, New Challenges (Baltimore: Johns Hopkins University Press, 2009): 125135.Google Scholar
Sass, J. O., Ensenauer, R., Roschinger, W., Reich, H., Steuerwald, U., Schirrmacher, O., Engel, K., Haberle, J., Andresen, B. S., Megarbane, A., Lehnert, W., and Zschocke, J., “2-Methylbutyryl-Coenzyme a Dehydrogenase Deficiency: Functional and Molecular Studies on a Defect in Isoleucine Catabolism,” Molecular Genetics and Metabolism 93, no. 1 (2008): 3035.CrossRefGoogle Scholar
Levy, H. L., “Lessons from the Past – Looking to the Future: Newborn Screening,” Pediatric Annals 32, no. 8 (2003): 505508.CrossRefGoogle Scholar
Maria Knoppers, B. and Laberge, C. M., eds., Genetic Screening: From Newborns to DNA Typing: Proceedings of the Workshop on Genetic Screening Held, at La. Sapinière, Québec (Canada) 13th-14th October 1989 for the Bi-Annual Meeting between the Quebec Network of Genetic Medicine and the New England. Regional Screening Program, with a Special Invitation Extended to L'association Française De Prévention Des Handicaps De L'enfant (New York: Elsevier Science, 1990).Google Scholar
U.S. Department of Health and Human Services, and Health Resources and Services Administration, “Secretary's Advisory Committee on Heritable Disorders in Newborns and Children,” available at <http://www.hrsa.gov/heritabledisorderscommittee/> (last visited August 10, 2010). (last visited August 10, 2010).' href=https://scholar.google.com/scholar?q=U.S.+Department+of+Health+and+Human+Services,+and+Health+Resources+and+Services+Administration,+“Secretary's+Advisory+Committee+on+Heritable+Disorders+in+Newborns+and+Children,”+available+at++(last+visited+August+10,+2010).>Google Scholar
Collins, F. S., The Language of Life: DNA and the Revolution in Personalized Medicine (New York: Harper Collins, 2010): At 208.Google Scholar
Cody, J. D. M., “An Advocate's Perspective on Newborn Screening Policy,” in Baily, M. A. and Murray, T. H., Ethics and Newborn Screening: New Technologies, New Challenges (Baltimore, Johns Hopkins University Press, 2009): 5888.Google Scholar
Genetics and Public Policy Center, “DTC Genetic Testing Companies,” available at <http://www.dnapolicy.org/resources/AlphabetizedDTCGeneticTestingCompanies.pdf> (last visited August 10, 2010).+(last+visited+August+10,+2010).>Google Scholar
Pollack, A., “Consumers Slow to Embrace the Age of Genomics,” New York Times, March 20, 2010, at B1.Google Scholar
US Food and Drug Administration, “Letters to Industry,” available at <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm111104.htm> (last visited August 10, 2010).+(last+visited+August+10,+2010).>Google Scholar
Committee on Bioethics, American Academy of Pediatrics, “Ethical Issues with Genetic Testing in Pediatrics,” Pediatrics 107, no. 6 (2001): 14511455; Harper, P. S., and Clarke, A., “Should We Test Children for “Adult” Genetic Diseases?” The Lancet 335, no. 8699 (1990): 12051206; Clarke, A., “The Genetic Testing of Children: Working Party of the Clinical Genetics Society (UK),” Journal of Medical Genetics 31, no. 10 (1994): 785797; Wertz, D. C., Fanos, J. H., and Reilly, P. R., “Genetic Testing for Children and Adolescents: Who Decides?” JAMA 272, no. 11 (1994): 875881; Hoffmann, D. E. and Wulfsberg, E. A., “Testing Children for Genetic Predispositions: Is It in Their Best Interest?” Journal of Law Medicine & Ethics 23, no. 4 (1995): 331344. But see Robertson, S. and Savulescu, J., “Is There a Case in Favour of Predictive Genetic Testing in Young Children?” Bioethics 15, no. 1 (2001): 2649.Google Scholar
Beleno v. Lakey, SA-09-CA-188-FB, (U.S. Dist.Ct., W.D. Tex. 9/17/2009), available at <http://www.genomicslawreport.com/wp-content/uploads/2010/01/Beleno-order.pdf> (order regarding defendants' motion to dismiss and defendants' motion to dismiss or for summary judgment based on mootness) (last visited August 10, 2010).+(order+regarding+defendants'+motion+to+dismiss+and+defendants'+motion+to+dismiss+or+for+summary+judgment+based+on+mootness)+(last+visited+August+10,+2010).>Google Scholar
Root, J., “Texas Officials Agree to Destroy Babies' Blood Samples after Settling Lawsuit,” Dallas Morning News, available at <http://www.texascivilrightsproject.org/?p=1822> (last visited August 10, 2010).Google Scholar
Bearder v. State of Minnesota, 27-CV-09-5615, (Dist. Ct., Hennepin Cty, MN, 11/24/2009), available at <http://www.workplaceprivacyreport.com/uploads/file/Bearder%20Decision%281%29-pdf> (order granting motion to dismiss) (last visited August 10, 2010).+(order+granting+motion+to+dismiss)+(last+visited+August+10,+2010).>Google Scholar
Minn.Stat.Ann. §§ 144.125–8 (2010).Google Scholar
Michigan Department of Community Health, “Michigan Biotrust for Health,” <http://www.michigan.gov/mdch/0,1607,7-132-2942_4911_49l6-232933--,00.html> (accessed August 10, 2010).+(accessed+August+10,+2010).>Google Scholar
Department of Health and Human Services, “Health Information Technology for the Future of Health and Care,” available at <http://healthit.hhs.gov/portal/server.pt> (last visited August 10, 2010).+(last+visited+August+10,+2010).>Google Scholar
Collins, F. S., The Language of Life: DNA and the Revolution in Personalized Medicine (New York: Harper Collins, 2010): At 44.Google Scholar